Zhengzhou, China – MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") attended the 2nd Shaolin Interventional Neurosurgical Conference and 5th Central China Cerebrovascular Disease Forum (SINC & CCDF) which was held from November 8 to 10 and brought together domestic and foreign healthcare professionals in the areas of neurosurgery and cerebrovascular diseases to discuss scientific topics and improve surgical skills. MicroPort® NeuroTech presented at SINC & CCDF Tubridge® Vascular Reconstruction Device ("Tubridge®") and other innovative devices. The attending healthcare professionals were deeply impressed with the company's integrated neurovascular interventional solutions.
During the “Forum for Aneurysms, Brain AVM, and Cerebrospinal and Vascular Disease Combined Procedure”, Professor Li Li from Henan Provincial People’s Hospital gave a speech titled “The Single Center Experience and Edited Case of Tubridge®”. Professor Li Li presented a comprehensive review of the application experience of Tubridge® in combination with the cases performed at the hospital, which was followed by edited cases to deepen the audience’s understandings of the mesh stent’s key application essentials. Professor Xiaodong Xie from West China Hospital of Sichuan University spoke under the title of “Clinical Application of WILLIS® Intracranial Stent Graft System”. He used his own rich clinical experience to discuss the application of WILLIS® Intracranial Stent Graft System in the treatment of aneurysms from the perspective of indications.
During the SINC & CCDF, MicroPort® NeuroTech hosted a Symposium on Review of 1,000 Tubridge® Cases. At the beginning of the symposium, Professor Tianxiao Li from Henan Provincial People’s Hospital and MicroPort® NeuroTech President Mr. Zhiyong Xie gave addresses respectively. Over the past more than one year since the launch of Tubridge®, over 50 mentors provided education and training at about 150 clinical centers to start a new chapter for the treatment of huge intracranial aneurysms. During the seminar session, a total of nine doctors gave lectures on Tubridge®, with the presence of guest commentators comprising Professor Professor Zhongxue Wu from Beijing Tian Tan Hospital Affiliated to Capital Medical University, Professor Xiaodong Xie from West China Hospital of Sichuan University, Professor Tielin Li from Zhujiang Hospital of Southern Medical University, and Professor Zhengwei Zhao from Tangdu Hospital. The doctors were Professor Yuxiang Gu from Huashan Hospital Affiliated to Fudan University, Professor Peng Liu from Beijing Tian Tan Hospital, Professor Li Li from Henan Provincial People’s Hospital, Professor Jieqing from Renji Hospital, Professor Qiang Li from Shanghai Changhai Hospital, Professor Sheng Guan from First Affiliated Hospital of Zhengzhou University, Professor Donghai Wang from Qilu Hospital of Shandong University, Professor Nan Lü from Shanghai Changhai Hospital, and Professor Bo Hong from Shanghai Changhai Hospital. They used their centers’ clinical experience to share their views on choices of indications, intraoperative skills and techniques, and how to reduce postoperative complications, followed by in-depth exchanges and discussions with the audience.
During the live case session, Shanghai Chang Hai Hospital and Henan Provincial People’s Hospital presented two Tubridge® live cases, in which the deployment operational skills of Tubridge® was comprehensively introduced to the audience through preoperative introduction and intraoperative explanation. The procedure achieved satisfactory immediate effects.
Tubridge® is an innovative device for the treatment of big and huge intracranial aneurysms, which resulted from 12 years of independent development. The device is also the first Chinese-made blood flow diverting device approved to launch in China. Since its launch in 2018, the device has received positive clinical feedbacks and endorsement from healthcare professionals. MicroPort® NeuroTech President Mr. Yongzhi Xie said: “MicroPort® NeuroTech will continue to listen intently to feedbacks from clinicians and continuously optimize the technologies and processes for our devices to provide doctors and patients with more neurovascular interventional solutions of higher quality.”